I'm LongbridgeAI, I can summarize articles.Citigroup analyst Geoff Meacham raised Eli Lilly's (LLY) price target to $1,600, citing a 45% upside and reiterating a Buy rating. He highlighted LLY's dominance in weight-loss drugs with a 60% market share and $14.9 billion in quarterly sales from obesity and diabetes treatments. The bullish outlook contrasts with rival Novo Nordisk's rebranding efforts as it seeks to regain market share.
Citigroup (C) has placed a new Street-high price target on Eli Lilly's (LLY) stock and sees 45% upside in the shares. Geoff Meacham, a five-star rated analyst with a 59% success rate, has placed a $1,600 price target on LLY stock, the highest on Wall Street. The price target from the Citigroup analyst is 45% higher than where Eli Lilly's shares currently trade.
Meacham also reiterated his Buy rating on LLY stock. In a note to clients, he said that Eli Lilly is the global leader in weight-loss drugs with a 60% market share. Eli Lilly's weight-loss and diabetes drugs are now doing $14.9 billion in combined quarterly sales, notes the analyst. Meacham also praised Eli Lilly for being a diversified pharmaceutical company with more than 40 active phase three clinical trials underway related to illnesses such as cancer, immunology and neuroscience.
Novo Nordisk Rebrands
In his note, Meacham highlights that Eli Lilly's stock has dropped 8% over the past month, presenting a buying opportunity to investors. The bullish note on LLY stock from Citigroup comes as rival pharmaceutical company Novo Nordisk (NVO) announced that it is rebranding. Going forward, the Danish company will be known simply as "Novo."
Novo Nordisk is rebranding and updating its corporate culture as the company works to win back market share in the weight-loss drug category. Management said they plan to deliver a detailed business strategy outlining more changes at Novo during a "Capital Markets Day" scheduled for Sept. 21. Novo continues to lag behind Eli Lilly in the obesity drug sector with 38% global market share.